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5 may occur at the gut wall before reaching the portal vein circulation, and the inhibitory effect must be saturated by substantial local concentrations of itraconazole in the gut lumen after 50 mg dosing.
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Introduction:
Fexofenadine is a selective histamine H1 receptor antagonist and is clinically effective in the treatment of seasonal allergic rhinitis and chronic urticaria as a first-line agent (Simpson et al., 2000) . Although fexofenadine is not metabolized by cytochrome P450s (CYPs), fexofenadine pharmacokinetics depends on the activity of P-glycoprotein (P-gp) (Cvetkovic et al., 1999; Putnam et al., 2002; Perloff et al., 2002) , as an efflux transporter expressed in the small intestine, liver, kidney and brain, and depends on several organic anion transporting polypeptide (OATP) family transporters (Cvetkovic et al., 1999; Niemi et al., 2005; Shimizu et al., 2005; Nozawa et al., 2004) as uptake transporters expressed in organs similar to P-gp. Recently, it has become increasingly evident that drug transporters have a pivotal role in pharmacokinetics of numerous drugs with therapeutic implications (Kim, 2002; Lin et al., 2003; Fromm, 2003) . Additionally, drug-drug and drug-food interaction reports relevant to fexofenadine have shown that rifampin (INN, rifampicin), St John's wort, fruit juice, and verapamil affected fexofenadine pharmacokinetics (Hamman et al., 2001; Dresser et al., 2002; Yasui-Furukori et al., 2005; Tannergren et al., 2003; Lemma et al., 2006) .
Itraconazole, an antifungal azole, has been used as a first-line treatment for patients This article has not been copyedited and formatted. The final version may differ from this version. with extensive or recalcitrant cutaneous fungal infections, mixed dermatophytoses, candidiasis and aspergillosis (Haria et al., 1996) . Itraconazole is extensively metabolized in the liver, and only one hydroxyitraconazole in over 30 metabolites has an antifungal activity similar to that of the parent drug (Haria et al., 1996) . Since itraconazole is a potent inhibitor of CYP3A activity in vitro and in vivo, itraconazole coadministration with a CYP3A substrate can result in clinically significant drug interaction (Dresser et al., 2000) . Similar to the inhibition of CYP3A-mediated metabolism, itraconazole significantly inhibits the in vitro activity of P-gp (Venkatakrishnan et al., 2000; Keogh et al., 2006) , and coadministration of itraconazole has reduced the clearance of poorly metabolized P-gp substrates such as digoxin (Jalava et al., 1997) and celiprolol (Lilja et al., 2003) in volunteer studies. The drug interaction between fexofenadine and itraconazole has been demonstrated in previous volunteer studies (Shon et al., 2005; Shimizu et al., 2006; Shimizu et al., in press) . We demonstrated that concomitant administration of 100 mg itraconazole with fexofenadine increased fexofenadine AUC by almost 3-fold after 4-day treatment of 100 mg itraconazole twice daily (Shimizu et al., 2006) , and the increase of fexofenadine AUC throughout the 6 days of itraconazole treatment at a 200 mg dose once daily was almost constant even though accumulation of plasma This article has not been copyedited and formatted. The final version may differ from this version. itraconazole concentration depended on duration of the 6-days treatment (Shimizu et al., in press). Interestingly, in these two different studies, no significant changes were found in elimination half-life and renal clearance reflecting elimination rates of fexofenadine.
These results therefore imply that the increase in fexofenadine AUC by itraconazole is probably due to the reduced first-pass effect by inhibiting P-gp activity. Furthermore, the higher plasma itraconazole concentrations from higher doses of itraconazole might affect OATP-mediated hepatic uptake and / or P-gp-mediated hepatic excretion of fexofenadine to greater extent, and thus have an increased effect on fexofenadine pharmacokinetics.
The aim of this study was to determine whether or not the extent of drug interaction of fexofenadine resulting from P-gp inhibition by itraconazole is dose dependent. We therefore investigated the effect of single administration of three different itraconazole doses, 50 mg, 100 mg and 200 mg on fexofenadine pharmacokinetics, and compared them with the pharmacokinetics of fexofenadine administered alone. We also evaluated the plasma concentration-time profiles of itraconazole, and examined their influence on fexofenadine pharmacokinetics.
METHODS:
Subjects.
Eleven healthy Japanese volunteers (6 males and 5 females) were enrolled in this study after giving written informed consent. Each subject was physically normal by clinical examination and routine laboratory testing and had no history of significant medical illness or hypersensitivity to any drugs. The mean (± SD) values of age and body weight of volunteers were 22.0 (± 1.2) years (range 20-24 years) and 56.9 (± 7.2) kg (range 46 -66 kg), respectively. This study was approved by the Ethics Committee of Hirosaki University School of Medicine.
Study design.
This randomized open-label study consisted of one control and three itraconazole phases, in which the volunteers received a tablet of 60 mg fexofenadine hydrochloride (Aventis Pharma Ltd., Tokyo, Japan) at 8 AM with 240 mL tap water after overnight fast.
In the three itraconazole phases, the volunteers were administered a 60 mg fexofenadine hydrochloride tablet with one, two or four 50mg itraconazole capsules (JANSSEN PHARMACEUTICAL K.K., Tokyo, Japan) simultaneously at 8 AM with 240 mL tap water after overnight fast. The order of the control and the itraconazole phases (50 mg, This article has not been copyedited and formatted. The final version may differ from this version. 
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1 0 100 mg and 200 mg) for each of the 11 volunteers in the study was randomly determined by the Latin-square method. Three volunteers in 3 groups participated in each respective sequence in the 4 phases of the study, and two volunteers participated in the sequence of 200 mg itraconazole, control, 50 mg itraconazole and 100 mg itraconazole phase. Each phase was separated by more than 2 weeks from other phases of the study as a washout period. The volunteers did not take any medication or fruit juices for at least 7 days before the control or the treatment phases, and no meal or beverages were allowed until 4 hours after the administration of fexofenadine.
Plasma and urine collections and determination of fexofenadine, itraconazole, and hydroxyitraconazole.
Blood samples (10 mL each) were drawn into heparinized tubes before and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of fexofenadine, and plasma was separated immediately. Just before fexofenadine administration, a spot of urine was collected as a blank sample. After fexofenadine administration the urine was collected from 0 to 48 hours. The plasma and urine samples were stored at -20 °C until assayed.
Plasma and urine concentrations of fexofenadine were determined by the high-performance liquid chromatography (HPLC) method developed in our laboratory
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1 1 (Uno et al., 2004) . In brief, 10 µ L (100 ng) of diphenhydramine as an internal standard and 1 mL of 0.2 M acetate buffer (pH 4.0) were added to 1 mL of plasma or urine samples. Samples were purified with C18 minicolumns (BondElute C18, 500 mg packing in 3 mL cartridge, Varian, Palo Alto, CA), and fexofenadine and the internal standard were eluted in 1 mL methanol. After the eluates were evaporated with air, the residues were dissolved with a HPLC mobile phase. The flow rate was 1.0 mL/min and the column was maintained at 50 ˚C. The peak was detected with a RF-10AXL fluorescence detector monitored at an excitation wavelength of 220 nm and an emission wavelength of 290 nm, and a CLASS-VP integrator (Shimadzu CO., Kyoto, Japan). The between-day coefficients of variation (CV) and relative errors were 1.3% and -2.7% at 50 ng/mL (n = 5), respectively. The limit of quantification was 1.0 ng/mL. Plasma and urine samples from the itraconazole treatment did not have any interfering peak for the fexofenadine assay, and the plasma and urine samples before each fexofenadine administration had no fexofenadine peak detected in the assay.
Plasma concentrations of itraconazole and hydroxyitraconazole were determined by the HPLC method developed in our laboratory (Uno et al., 2006) . In brief, after 30 µ L of an internal standard (R051012, 10 µ g/mL) and 0.1 mL of 0.5M disodium hydrogen phosphate were added to 1 mL of plasma, the mixture was extracted with This article has not been copyedited and formatted. The final version may differ from this version. clean-up and separation, respectively. The peak was detected with an ultraviolet detector set at a wavelength of 263 nm. The validated concentration ranges of this method were 3-500 ng/mL and 3-1000 ng/mL for itraconazole and hydroxyitraconazole, respectively.
The between-day coefficients of variation (CV) was 2.3% at 4 ng/mL (n = 6), and 2.4% at 4 ng/mL (n = 6) for itraconazole and hydroxyitraconazole, respectively. The limit of quantification was 2 ng/mL for both itraconazole and hydroxyitraconazole.
Pharmacokinetic data analysis.
The maximum plasma concentration (Cmax) and the time to reach Cmax (tmax) of fexofenadine, itraconazole, and hydroxyitraconazole were determined directly from the observed data. The elimination rate constant (ke) of fexofenadine was obtained by linear regression analysis by use of at least 3 sampling points of the terminal log-linear declining phase to the last measurable concentration. The elimination half-life (t1/2) This article has not been copyedited and formatted. The final version may differ from this version. 
Statistical analysis.
The results are expressed as mean ± SD. Repeated-measures ANOVA was used for statistical differences in the mean pharmacokinetic parameters between the phases, and 
RESULTS:
None of the enrolled subjects reported any adverse events during the study and they completed all phases according to the study protocol.
Plasma concentrations and pharmacokinetics of fexofenadine.
Mean plasma fexofenadine concentration-time profiles following a single oral administration of 60 mg fexofenadine hydrochloride in the control and the three itraconazole phases are shown in Figure 1 Cmax (p = 0.636) and CLrenal (p = 0.495) between the doses of itraconazole. There was no significant difference in tmax or t1/2 of fexofenadine between the phases.
Urinary excretion of fexofenadine.
Although the renal clearance of fexofenadine was relatively constant between the control (63.5 ± 15.8 mL/hr/kg) and the itraconazole phases (58.9 ± 19.6, 65.9 ± 27.0 and 64.1 ± 24.6 mL/h/kg for 50 mg, 100 mg and 200 mg itraconazole, respectively), there was a significant difference in the amount of fexofenadine excreted into the urine within 48 hours (Table 1) . However, the different doses of itraconazole did not affect the amount of fexofenadine excreted into the urine (Table 1) . ± 1285 ng hr/mL on day 6).
Plasma
Itraconazole coadministration has been reported to increase serum concentrations of digoxin, a substrate of P-gp, most probably by inhibiting P-gp in the small intestine and kidneys (Partanen et al., 1996; Jalava et al., 1997; Greiner et al., 1999) . In the present study, although the itraconazole treatment significantly increased the amount of fexofenadine excreted into the urine within 48 hours, mean CLrenal of fexofenadine was relatively constant between the control and the itraconazole phases. Therefore, in the interaction between fexofenadine and itraconazole, the effect of itraconazole could be due to a combination of increased bioavailability by inhibiting P-gp and reduced organic clearance without CLrenal and distribution volume by inhibiting P-gp and / or other transporters, because fexofenadine is a substrate of several OATPs (Cvetkovic et al., 1999; Niemi et al., 2005; Shimizu et al., 2005; Nozawa et al., 2004) as well as P-gp (Cvetkovic et al., 1999; Putnam et al., 2002; Perloff et al., 2002) . Itraconazole might This article has not been copyedited and formatted. The final version may differ from this version. tmax, observed time to reach the maximum plasma concentration; Cmax, observed maximum plasma concentration; t1/2, elimination half-life; AUC(0-∞), area under plasma drug concentration-time curve from 0 hours extrapolated to infinity; CL/F, apparent oral clearance; Vd/F, apparent volume of distribution; Ae, amount of fexofenadine excreted into urine; CLrenal, the renal clearance.
P-values, compared with the control phase. Not significant differences found in the itraconazole treatments.
This article has not been copyedited and formatted. The final version may differ from this version. tmax, observed time to reach the maximum plasma concentration; Cmax, observed maximum plasma concentration; AUC(0-48), area under plasma drug concentration-time curve from 0 to 48 hours after administration; CL/F, apparent oral clearance.
P-values, compared with the 50 mg itraconazole treatment.
